XRTX (XORTX Therapeutics) Unearned Premiums

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

XRTX XORTX Therapeutics Inc XRTX
32 GF Score
Price $2.40
! 1 Warning Sign
View Full Analysis

What is XORTX Therapeutics Unearned Premiums?

Unearned Premiums only applies to insurance companies.

XRTX
32GF Score
XORTX Therapeutics Inc XRTX
Unearned Premiums is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

XORTX Therapeutics Business Description

Other Exchanges ANU:GermanyXRTX:Canada
Address 3710 - 33rd Street NW, Calgary, AB, CAN, T2L 2M1
XORTX Therapeutics Inc is a clinical-stage pharmaceutical company focused on developing therapies to treat gout and progressive kidney disease modulated by aberrant purine and uric acid metabolism in orphan disease indications such as allopurinol-intolerant gout and autosomal dominant polycystic kidney disease, as well as more prevalent type 2 diabetic nephropathy and fatty liver disease. Its focus is on developing products to slow and/or reverse the progression of these diseases. The Company operates in one reportable operating segment: the development and commercialization of therapies to treat hyperuricemia-related diseases.
32GF Score

Get the complete analysis for XRTX

Unearned Premiums is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.40
Price